Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 12/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | CALML3 | P27482 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210281 | 0.85 | IDH1 (0.38) | IDH1MAOAMAOBCALML3LMNA | |
| SCHEMBL5231089 | 0.84 | CALML3 (0.59) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5834842 | 0.84 | CALML3 (0.59) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL7078516 | 0.84 | CALML3 (0.59) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL7092070 | 0.82 | CALML3 (0.49) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL8822070 | 0.79 | MAOA (0.67) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5234526 | 0.77 | MAOB (0.48) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5834806 | 0.77 | MAOB (0.48) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5834562 | 0.76 | F10 (0.38) | IDH1MAOAMAOBCALML3LMNA | |
| SCHEMBL5230526 | 0.76 | MAOA (0.56) | MAOAMAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | IDH1 2244/4885MAOA 2239/4885MAOB 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.